Synthera- Bind AI

Synthera

Synthera- Bind AI

Synthera: Accelerating life-saving drug discovery with AI that thinks like a scientist, codes like a chemist, and heals like a doctor.

Littleton, MA, USA

USA

For-profit, including B-Corp or similar models

—

The U.S. pharmaceutical industry is facing a crisis of inefficiency: developing a single drug costs an average of $2.23 billion, with a staggering 90% failure rate in clinical trials (Deloitte, 2024). This inefficiency not only inflates drug prices but delays critical treatments—particularly in oncology, rare diseases, and antimicrobial resistance—reaching patients when they’re needed most. The average time from discovery to market exceeds 10 years, contributing to over 100,000 avoidable deaths annually due to lack of timely drug access (RAND, 2023). Despite record R&D investments, return on pharma innovation in the U.S. dropped to just 1.2% in 2024, the lowest in over a decade. Moreover, post-approval drug shortages rose by 30%, exposing gaps in scalability and prediction (FDA, 2024). Globally, nearly 2 billion people still lack access to essential medicines (WHO, 2024). Many LMICs depend on U.S.-led innovation pipelines for affordable generics and treatment models. Synthera addresses these systemic failures with an AI-powered drug discovery platform designed to cut R&D costs, improve success rates, and accelerate the pipeline—delivering more effective, life-saving treatments faster and cheaper, starting in the U.S. and expanding globally.

Synthera is an AI-powered drug discovery engine that slashes the time and cost of identifying new therapeutics by transforming complex R&D into a rapid, data-driven process. Built for researchers, startups, and pharmaceutical teams, Synthera generates and evaluates novel drug candidates in minutes using cutting-edge AI. Users input disease targets (e.g., protein, gene, or pathway), and Synthera autonomously designs small molecules using a custom-trained variational autoencoder (VAE), then screens them using AI models for binding affinity, toxicity, ADME, QSAR, and resistance profiling. We use multimodal deep learning—Transformers, TabNet, and graph neural networks (GNNs)—to analyze compound libraries, omics data, and protein structures at scale. Hosted securely on AWS, Synthera processes over 10 million compounds per hour, achieving 80%+ predictive accuracy for binding affinity and 90%+ precision in ADME/toxicity filtration. Compared to traditional pipelines, we reduce early-stage R&D costs by 65% and timelines by 70%. Already, we've onboarded 150+ early-access users, generated 2,000+ novel compounds, and are being piloted at Yale, MGH, and Harvard Medical School.

Synthera directly serves early-career researchers, biotech startups, and academic labs—especially those without access to costly infrastructure for drug discovery. These groups represent a powerful yet underserved population: over 1.3 million biomedical researchers in the U.S. alone, with thousands more in low-resource settings globally. Yet fewer than 15% have access to high-throughput screening, computational chemistry tools, or in-house AI expertise. These innovators often have brilliant ideas—but lack the tools to act on them. The result? Promising cures for cancer, rare diseases, and neurodegenerative conditions remain locked in notebooks or lost in grant rejections. Synthera gives them a seat at the table. By offering cloud-based, AI-driven drug discovery tools at a fraction of the traditional cost, Synthera empowers them to go from “What if?” to molecule design, feasibility scoring, and preclinical modeling—all in under 24 hours. For a researcher trying to save a child with a drug-resistant brain tumor, or a founder racing to stop a global superbug, that speed and accessibility isn’t just technical—it’s life-changing. Synthera levels the playing field in science, putting powerful discovery tools into the hands of those with the boldest ideas and the greatest need.